Home2AB • FRA
add
Barinthus Biotherapeutics PLC - ADR
Previous close
€0.90
Day range
€0.82 - €0.82
Year range
€0.76 - €3.24
Market cap
35.93M USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 14.97M | — |
Operating expense | 23.72M | 49.31% |
Net income | -8.11M | 42.34% |
Net profit margin | -54.21 | — |
Earnings per share | -0.21 | 43.24% |
EBITDA | -8.48M | 41.43% |
Effective tax rate | 0.04% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 106.10M | -33.81% |
Total assets | 188.69M | -17.95% |
Total liabilities | 29.23M | -14.95% |
Total equity | 159.46M | — |
Shares outstanding | 40.23M | — |
Price to book | 0.22 | — |
Return on assets | -12.19% | — |
Return on capital | -13.40% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -8.11M | 42.34% |
Cash from operations | -18.20M | -62.61% |
Cash from investing | -114.00K | -216.67% |
Cash from financing | 465.00K | 910.87% |
Net change in cash | -11.67M | 8.25% |
Free cash flow | -18.26M | -1,948.34% |
About
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia
Founded
2016
Website
Employees
130
